Inclusion Criteria:

• Histologically/cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC.
• Age > 18 years.
• ECOG PS 0-1.
• No prior chemotherapy for NSCLC.
• Measurable disease by RECIST criteria.
• Signed IRB-approved informed consent.
• Adequate bone marrow function defined by: peripheral absolute neutrophil count (ANC) >1500/microL, hemoglobin >9.0 g/dL, and platelet count >100,000/microL.
• Adequate renal function as defined by serum creatinine level less than institutional upper limit of normal (ULN) or calculated/measured creatinine clearance > 65 mL/min.
• Adequate liver function defined as: serum total bilirubin <ULN, serum aspartate aminotransferase (AST) <2.5 times ULN.
• Estimated life expectancy >12 weeks.

Exclusion Criteria:

• Untreated clinically active brain metastasis.
• Radiotherapy within 2 weeks prior to registration or previous irradiation to the only area of measurable disease.
• Treatment with any investigational therapy within 4 weeks prior to registration.
• Prior therapy with an agent that is known to specifically and directly target the EGFR pathway.
• History of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last 5 years.
• Patients in their reproductive age group should consent to use an effective method of birth control while on treatment and for at least 3 months thereafter. Patients who are breast-feeding, or have a positive pregnancy test will be excluded from the study.
• Major surgery within 3 weeks prior to registration.
• Use of immunosuppressive agents including systemic corticosteroids within 4 weeks prior to registration (corticosteroids are permitted as physiological replacement therapy or as supportive care for nausea and emesis).
• Known history of human immunodeficiency virus infection.
• Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator.
• Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction.
• Concurrent serious infection.
• History of known hypersensitivity to docetaxel or other drugs formulated with polysorbate 80.
• History of prior severe infusion reaction to a monoclonal antibody.
• Patient has >Grade 2 peripheral neuropathy within 14 days prior to registration